<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01074099</url>
  </required_header>
  <id_info>
    <org_study_id>Harvest 2009-1</org_study_id>
    <nct_id>NCT01074099</nct_id>
  </id_info>
  <brief_title>Feasibility Study of BMAC Enhanced CABG</brief_title>
  <official_title>Feasibility Study of Autologous Concentrated Bone Marrow Nucleated Cell Therapy for Congestive Heart Failure Patients Undergoing Treatment With Coronary Artery Bypass Grafting(CABG) Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harvest Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Harvest Technologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing CABG will have 60 mL of bone marrow drawn, concentrated in a SmartPRep2
      centrifuge and have the concentrated nucleated cells injected into areas of ischemic
      myocardium
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing CABG will have 60 mL of bone marrow drawn, concentrated in a SmartPRep2
      centrifuge and have the concentrated nucleated cells injected into areas of ischemic
      myocardium. Control subjects will undergo CABG only
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Pilot results in change to protocol, new study needed.
  </why_stopped>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cardiac Status (Classification)</measure>
    <time_frame>Through 12 months post treatment</time_frame>
    <description>A change in cardiac status as determined by the New York Heart Association (NYHA) or Canadian Cardiovascular Society (CCS) classification evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>through 1 Year post tx</time_frame>
    <description>as measured by frequency and severity of adverse events</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CABG only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMAC enhanced CABG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of concentrated bone marrow nucleated cells (BMAC) as an adjunct to CABG surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMAC</intervention_name>
    <description>Injection of BMAC into ischemic myocardium during CABG</description>
    <arm_group_label>BMAC enhanced CABG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CABG only</intervention_name>
    <description>Control subjects will undergo CABG surgery without BMAC injection</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt; 18 years and ability to understand the planned treatment.

          -  Patients with ischemic congestive heart failure requiring by pass surgery

          -  Congestive heart failure with ejection fraction ≤ 40%.

          -  Serum bilirubin, SGOT and SGPT ≤2.5 time the upper level of normal.

          -  Serum creatinine &lt; 3.0 or no dialysis.

          -  NYHA performance status ≥ 3.

          -  Negative pregnancy test (in women with childbearing potential).

          -  Subject has read and signed the IRB approved Informed Consent form

          -  Hematocrit ≥ 28.0%, White Blood Cell count ≤ 14,000, Platelet count ≥ 50,000,
             Creatinine ≤ 3.0 mg / Dl, and/or no dialysis, INR ≤ 1.6 unless on Coumadin, or PTT
             &lt;1.5 x control (to avoid bleeding complications) Patients on Coumadin will be
             corrected prior to the procedure and must have an INR&lt;1.6 at the time of
             randomization/surgery

        Exclusion Criteria:

          -  Female who is pregnant or nursing, or of child bearing potential and is not using a
             reliable birth control method, or who intend to become pregnant during the tenure of
             this study.

          -  History of Prior Radiation Exposure for oncological treatment.

          -  History of Bone Marrow Disorder (especially NHL, MDS) that prohibit transplantation.

          -  History of abnormal Bleeding or Clotting.

          -  History of Liver Cirrhosis.

          -  Acute Myocardial Infarction &lt; 4 weeks from treatment date.

          -  Known active malignancy or results outside of normal limits from the following tests:
             PAP, Chest X-ray, PSA, Mammogram, Hemoccult unless follow-up studies reveal patient to
             be cancer free.

          -  Active clinical infection being treated by antibiotics within one week of enrollment

          -  Terminal renal failure with existing dependence on dialysis

          -  Inability or unwillingness to comply with the treatment protocol, follow-up, research
             tests, or give consent.

          -  Unable to have 250cc bone marrow harvested.

          -  Medical risk that precludes anesthesia or ASA Class 5

          -  History of ventricular arrhythmia if AICD is not present.

          -  History of ventricular aneurysm.

          -  Concurrent surgery such as CABG with valve surgery.

          -  Minimally Invasive bypass surgery

          -  Life expectancy &lt;6 months due to concomitant illnesses

          -  Treatment with immunosuppressant drugs (including Prednisone &gt; 5 mg per day)

          -  Patients undergoing urgent by pass surgical procedure

          -  Patients with HGB A1C &gt; 8.5%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amit Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2010</study_first_submitted>
  <study_first_submitted_qc>February 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2010</study_first_posted>
  <results_first_submitted>August 18, 2014</results_first_submitted>
  <results_first_submitted_qc>December 14, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2016</results_first_posted>
  <last_update_submitted>December 14, 2015</last_update_submitted>
  <last_update_submitted_qc>December 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>CABG only
CABG only: Control subjects will undergo CABG surgery without BMAC injection</description>
        </group>
        <group group_id="P2">
          <title>BMAC Enhanced CABG</title>
          <description>Injection of concentrated bone marrow nucleated cells (BMAC) as an adjunct to CABG surgery
BMAC: Injection of BMAC into ischemic myocardium during CABG</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>CABG only
CABG only: Control subjects will undergo CABG surgery without BMAC injection</description>
        </group>
        <group group_id="B2">
          <title>BMAC Enhanced CABG</title>
          <description>Injection of concentrated bone marrow nucleated cells (BMAC) as an adjunct to CABG surgery
BMAC: Injection of BMAC into ischemic myocardium during CABG</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Cardiac Status (Classification)</title>
        <description>A change in cardiac status as determined by the New York Heart Association (NYHA) or Canadian Cardiovascular Society (CCS) classification evaluation</description>
        <time_frame>Through 12 months post treatment</time_frame>
        <population>Study was terminated after enrollment of only 5 patients. The data were not analyzed for efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>CABG only
CABG only: Control subjects will undergo CABG surgery without BMAC injection</description>
          </group>
          <group group_id="O2">
            <title>BMAC Enhanced CABG</title>
            <description>Injection of concentrated bone marrow nucleated cells (BMAC) as an adjunct to CABG surgery
BMAC: Injection of BMAC into ischemic myocardium during CABG</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cardiac Status (Classification)</title>
          <description>A change in cardiac status as determined by the New York Heart Association (NYHA) or Canadian Cardiovascular Society (CCS) classification evaluation</description>
          <population>Study was terminated after enrollment of only 5 patients. The data were not analyzed for efficacy.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety</title>
        <description>as measured by frequency and severity of adverse events</description>
        <time_frame>through 1 Year post tx</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>CABG only
CABG only: Control subjects will undergo CABG surgery without BMAC injection</description>
          </group>
          <group group_id="O2">
            <title>BMAC Enhanced CABG</title>
            <description>Injection of concentrated bone marrow nucleated cells (BMAC) as an adjunct to CABG surgery
BMAC: Injection of BMAC into ischemic myocardium during CABG</description>
          </group>
        </group_list>
        <measure>
          <title>Safety</title>
          <description>as measured by frequency and severity of adverse events</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From time of treatment through 1 year / study termination</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>CABG only
CABG only: Control subjects will undergo CABG surgery without BMAC injection</description>
        </group>
        <group group_id="E2">
          <title>BMAC Enhanced CABG</title>
          <description>Injection of concentrated bone marrow nucleated cells (BMAC) as an adjunct to CABG surgery
BMAC: Injection of BMAC into ischemic myocardium during CABG</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>sustained ventricular tachycardia</sub_title>
                <description>patient had an episode during the investigational procedure when the injection into the heart occurred. recovered without sequelae</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated early. Only 5 subjects were enrolled and they were followed for a year for safety data only. One efficacy data was collected.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Director of Clinical Operations</name_or_title>
      <organization>Harvest Technologies</organization>
      <phone>508-732-7530</phone>
      <email>CLI2011communication@harvesttech.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

